Variable | Good prognosis (n = 61) | Poor prognosis (n = 46) | p-value |
---|---|---|---|
Gender, Male | 29 (47.54) | 18 (39.13) | 0.385 |
Age | 13 (3–64) | 12.5 (2–72) | 0.738 |
Prodromal symptoms | 22 (36.07) | 18 (39.13) | 0.746 |
Abnormal behavior or cognitive dysfunction | 46 (75.41) | 41(89.13) | 0.071 |
Speech dysfunction | 27 (44.26) | 22 (47.82) | 0.714 |
Seizures | 46 (75.41) | 37 (80.43) | 0.537 |
Movement disorder | 36 (59.16) | 28 (60.87) | 0.847 |
Consciousness impairment | 2 (3.28) | 17 (36.96) | < 0.001 |
Autonomic dysfunction or central hypoventilation | 3 (4.92) | 15 (32.61) | < 0.001 |
CSF pleocytosis | 14 (22.95) | 24 (52.17) | 0.002 |
Elevated CSF protein | 13 (21.31) | 8 (17.39) | 0.613 |
Abnormal MRI | 23 (37.70) | 24 (52.17) | 0.135 |
Abnormal EEG | 41 (67.21) | 44 (95.65) | < 0.001 |
Tumor | 2 (3.28) | 2 (4.35) | 1.000 |
Early immunotherapy | 44 (72.13) | 37 (80.43) | 0.321 |